iogen (BIIB) said Monday that it has signed a deal with Dublin-based Alkermes (ALKS) to develop and market a drug in late-stage clinical trials to treat relapsing forms of multiple sclerosis.

Under the agreement, Biogen will receive an exclusive, worldwide license to market the experimental oral medicine, called ALKS 8700, and will pay Alkermes a royalty on worldwide scales in the mid-teens.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Biotech newsletter — The Readout

Your daily guide to what’s new in biotech.